PT-141 code is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-02-17. Where a claim depends on a specific study, the study is described rather than over-claimed.
Development of the peptide passed through several delivery formats, including an intranasal version tested in early trials and an injectable version that entered later clinical study. Regulatory approval for a subcutaneous product in the United States was granted in 2019 after review of controlled trials in premenopausal women. Outside the clinic, the compound circulates in research and non-pharmaceutical markets under its code name, where identity and purity vary considerably between suppliers. Synonyms appearing across technical literature include bremelanotide, PT-141, and Palatin 141.
PT-141 is the research designation for bremelanotide, a synthetic cyclic heptapeptide developed as a melanocortin receptor agonist. The peptide contains seven amino acids with an internal lactam bridge that constrains the backbone into a stable ring. Cyclisation of this kind improves resistance to enzymatic degradation relative to linear analogues. The compound was first explored for effects on melanin production, because several melanocortin receptors influence pigmentation. Its later association with sexual desire emerged from observations made during that early work, and the molecule became the subject of a separate development programme.
Approved use is narrow and jurisdiction-specific. In the United States, the injectable product is authorised for premenopausal women with acquired, generalised hypoactive sexual desire disorder, a diagnosis that requires documented distress. It is not approved for men, for postmenopausal women, or for use alongside hormonal contraceptives under the approved labelling. Outside regulated markets, the same peptide is frequently sold as a research chemical, where identity, purity, and sterility are not independently verified.
Bremelanotide is a synthetic cyclic heptapeptide developed as an analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation and appetite signalling. Its structure contains seven amino acid residues joined by a lactam bridge that closes the ring between two side chains. The molecular formula is C50H68N14O10 and the nominal molecular mass is near 1025 daltons. Much of the early laboratory literature refers to the same molecule by the development code PT-141.
The compound emerged from a research programme examining melanocortin analogues for effects on skin pigmentation. During early human studies, participants reported spontaneous erections as an unexpected side effect, which redirected development toward sexual function rather than tanning. An intranasal formulation was investigated in clinical trials but did not reach market approval. A subcutaneous injectable version later completed the regulatory process, and the nasal route does not appear in approved labelling.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Cyclic heptapeptide | Synthetic melanocortin analogue |
| Molecular formula | C50H68N14O10 | Corresponds to a mass near 1025 daltons |
| Appearance | White to off-white powder | Lyophilised solid before reconstitution |
| Solubility | Soluble in water and polar solvents | Poor solubility in nonpolar media |
| Common synonyms | Bremelanotide, PT-141 | Code name and international name used interchangeably |
Early clinical work used an intranasal formulation, and later programmes switched to subcutaneous delivery for more consistent absorption. A subcutaneous product received regulatory approval in the United States in 2019 for premenopausal women with acquired, generalised hypoactive sexual desire disorder. Approval followed phase 3 trials in which active treatment separated from placebo on desire and distress measures, though the average difference was modest. Labeling carries a caution about transient blood pressure elevation, so cardiovascular history is assessed before prescribing. Questions about durability of benefit beyond several months remain open.
Published discussion sits at the intersection of peptide chemistry, neuroendocrinology and sexual medicine. Trial reports emphasise change scores on validated instruments, while mechanistic papers focus on hypothalamic circuits and receptor selectivity. Because placebo response in this field is large, effect sizes are usually reported with confidence intervals rather than as isolated averages. Reviews note that female and male data sets are not interchangeable and should be read separately. Diagnostic terminology has been revised over time, which complicates comparison between older and newer studies.
Bremelanotide is a synthetic cyclic heptapeptide that acts on a family of G-protein-coupled receptors. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous peptide associated with pigmentation and several central signalling pathways. A lactam bridge constrains the ring and slows enzymatic breakdown, which distinguishes it from the linear parent molecule. Research interest moved over time from pigment biology toward central nervous system effects, particularly circuits connected to sexual desire. Parenteral delivery is used because oral bioavailability is poor.
PT-141 is a synthetic cyclic heptapeptide whose development code is bremelanotide. It belongs to the class of melanocortin receptor agonists and acts by mimicking endogenous peptide hormones. The compound originated from research on melanotan II, where investigators exploring derivatives found distinct pharmacological features. Unlike the parent compound, PT-141 showed effects on pathways related to sexual desire and function in early studies, prompting its development as a separate candidate. Its molecular design aimed to separate receptor activity from pigmentary effects.
The molecular backbone consists of seven amino acid residues joined into a ring through a disulfide bridge. This cyclic conformation is critical for receptor binding. The sequence includes an acetylated N-terminus and an amidated C-terminus, modifications that improve resistance to enzymatic breakdown. One residue is in the D-configuration, a feature that further stabilizes the peptide against protease activity. Together, the ring structure and specific stereochemistry determine selectivity among melanocortin receptor subtypes.
Reverse-phase high-performance liquid chromatography is the standard method for assessing purity. Mass spectrometry confirms molecular identity and detects sequence variants or truncation products. Ultraviolet absorbance at 214 or 280 nm is used for quantification, with the choice depending on the peptide sequence. Method validation typically addresses linearity, limit of detection, and precision across a defined concentration range. Impurity profiling may also employ ion-exchange or size-exclusion chromatography, and these techniques complement one another.
Certificate of analysis documents usually report purity percentage, molecular weight, and appearance. Researchers verify identity by comparing observed and theoretical mass values. Chain-of-custody records and batch numbers help trace material from source to experiment. Independent verification of supplier claims is considered good practice when material identity is critical to a study. Records should include the storage history of each aliquot, and unexpected deviations in appearance or solubility warrant re-testing before use.
Lyophilized peptide material is generally stored at -20 °C or below to limit degradation, while reconstituted solutions are less stable and are typically kept refrigerated and protected from light. Repeated freeze-thaw cycles can accelerate aggregation and should be minimized. Stability for any specific lot depends on purity, moisture content, and packaging. Handling in a temperature-controlled environment reduces variability across replicates, and exposure to ambient humidity during weighing can introduce error. Aliquotting reduces the number of times a stock container is opened.
Most current research calls for a coordinated, multifaceted approach to infection prevention and containment, and the Centers for Disease Control and Prevention have issued preliminary guidelines for the control of CRE transmission. Experts advocate for a proactive approach, based on the belief that it will be most cost-effective to combat the problem before it is established. However, when immediate financial and personnel resources are limited, healthcare administrators may be forced to respond reactively, aiming to reduce any further transmission. Although a consensus exists for the need of prevention protocols, infection control practices often vary among hospitals, even within close geographic area. In a survey of 15 hospitals within the Toronto area, many hospitals employed varying combinations of basic infection control practices. Eight different practices were observed among the 15 hospitals, some of which included in the most recent publication of guidelines from the Public Health Agency of Canada. Some of these recommendations include laboratory testing, active surveillance, screening (rectal swab, urine culture), hand hygiene, personal protective equipment, environmental cleaning, laundry waste management, and isolation with dedicated equipment and nursing staff. However, only five hospitals had written policies describing how to respond to an outbreak.
RF(Arg-Phe)amide family 26 amino acid peptide, also known as P518, is a human protein. The 26-amino acid RF-amide peptide, P518 functions as a high-affinity ligand of GPR103. Both GPR103 and P518 precursor mRNA exhibited highest expression in brain. The 43-amino acid QRFP peptide, a longer form of the P518 peptide is necessary to exhibit full agonistic activity with GPR103. Intravenous administration QRFP caused release of aldosterone, suggesting that QRFP and GPR103 regulate adrenal function.
== Functions == The integumentary system has multiple roles in maintaining the body's equilibrium. All body systems work in an interconnected manner to maintain the internal conditions essential to the function of the body. The skin has an important job of protecting the body and acts as the body's first line of defense against infection, temperature change, and other challenges to homeostasis. Its main functions include:
The wavelength of the UV light for the lower TOC waters must be less than 200 nm and is typically 184 nm generated by a low pressure Hg vapor lamp. The 184 nm UV light is energetic enough to break the water molecule into OH and H radicals. The hydrogen radicals quickly react to create H2. The equations follow: H2O + hν (185 nm) → OH• + H • and H • + H • → H2 Different types of UPW TOC Analyzers IC (Inorganic Carbon) = CO2 + HCO−3 + CO2−3 TC (Total Carbon) = Organic Carbon + IC TOC (Total Organic Carbon) = TC – IC H2O + hν (185 nm) → OH• + H • S2O2−8 + hν (254 nm) → 2 SO−4 • SO−4 • + H2O → HSO−4 + OH •
Location of action The central location of action (effect) of the fat cell-specific hormone leptin is the hypothalamus, a part of the brain and thus of the central nervous system. Non-hypothalamic targets of leptin are referred to as peripheral targets. There is a different relative importance of central and peripheral leptin interactions under different physiologic states, and variations among species. Mode of action Leptin acts directly on leptin receptors in the cell membrane of different types of cells in the human body in particular, and in vertebrates in general. The leptin receptor is found on a wide range of cell types. It is a single-transmembrane-domain type I cytokine receptor, a special class of cytokine receptors. Further, leptin interacts with other hormones and energy regulators, indirectly mediating the effects of: insulin, glucagon, insulin-like growth factor, growth hormone, glucocorticoids, cytokines, and metabolites. Function The primary function of the hormone leptin is the regulation of adipose tissue mass through central hypothalamus mediated effects on hunger, food energy use, physical exercise, and energy balance. Outside the brain, in the periphery of the body, leptin's secondary functions are: modulation of energy expenditure, modulation between fetal and maternal metabolism, and that of a permissive factor in puberty, activator of immune cells, activator of beta islet cells, and growth factor.
Sources: en.wikipedia.org
The oldest known constructed roadways are the stone-paved streets of the city-state of Ur, dating to c. 4,000 BCE, and timber roads leading through the swamps of Glastonbury, England, dating to around the same period. The first long-distance road, which came into use around 3,500 BCE, spanned 2,400 km from the Persian Gulf to the Mediterranean Sea, but was not paved and was only partially maintained. Around 2,000 BCE, the Minoans on the Greek island of Crete built a 50 km road leading from the palace of Gortyn on the south side of the island, through the mountains, to the Palace of Knossos on the north side of the island. Unlike the earlier road, the Minoan road was completely paved. Ancient Minoan private homes had running water. A bathtub virtually identical to modern ones was unearthed at the Palace of Knossos. Several Minoan private homes also had toilets, which could be flushed by pouring water down the drain. The ancient Romans had many public flush toilets, which emptied into an extensive sewage system. The primary sewer in Rome was the Cloaca Maxima; construction began on it in the sixth century BCE, and it is still in use today. The ancient Romans also had a complex system of aqueducts, which were used to transport water across long distances. The first Roman aqueduct was built in 312 BCE. The eleventh and final ancient Roman aqueduct was built in 226 CE. Put together, the Roman aqueducts extended over 450 km, but less than 70 km of this was above ground and supported by arches.
Among these mixed communities, the largest Christian populations in Druze towns are found in Maghar, followed by Isfiya and Peki'in. Conversely, the largest Druze communities in predominantly Christian towns are located in Rameh, followed by Kafr Yasif. Before Israel's occupation, Christians accounted for 12% of the population of the Golan Heights, and they tended to have a high representation in science and in the white collar professions. But a few Christians remain of a much larger community that left the area. In 2010 more than 8,000 Christians lived in Druze-majority towns and cities in Israel, including Daliyat al-Karmel, Ein Qiniyye, Hurfeish, Isfiya, Kisra-Sumei, Majdal Shams, Maghar and Peki'in. Additionally, in 2016, more than 2,700 Druze lived in Rameh and Kafr Yasif, which are Christian-majority towns located in the Galilee region, and more than 12,000 Christians and 9,800 Druze lived Abu Snan and Shefa-Amr, which have a Muslim majority. Before 1948, some Druze towns such as Beitegen, Julis, Sajur and Yarka were inhabited by small Christian communities.
Some medical organizations take the position that it carries prophylactic health benefits that outweigh the risks, while others hold that its medical benefits are not sufficient to justify it. Circumcision is one of the world's most common and oldest medical procedures, with 37–39% of men globally circumcised. Prophylactic usage originated in England during the 1850s and has since spread globally, becoming established as a way to prevent sexually transmitted infections. Beyond use as a prophylactic or treatment option in healthcare, circumcision plays a major role in many of the world's cultures and religions, most prominently Judaism and Islam. Circumcision is among the most important commandments in Judaism and considered obligatory. In some African and Eastern Christian denominations male circumcision is required. It is widespread in the United States, South Korea, the Philippines, Israel, Muslim-majority countries, and most of Africa. It is relatively rare for non-religious reasons in Latin America, Europe, Australia, most of Asia, and parts of Southern Africa. The origin of circumcision is not known with certainty, but the oldest documentation comes from ancient Egypt.
==== Reduction of particle size ==== Nanoparticles have been explored as a delivery system for various drugs, such as improving the oral bioavailability of drugs with poor absorption characteristics. However, this has not proved successful with CoQ10, although reports have differed widely. The use of aqueous suspension of finely powdered CoQ10 in pure water also reveals only a minor effect.
Sources: en.wikipedia.org
=== Death === De Duve died on 4 May 2013, at his home in Nethen, Belgium, aged 95. He decided to end his life by legal euthanasia, performed by two doctors and in the presence of his four children. He had been long suffering from cancer and atrial fibrillation, and his health problems were exacerbated by a recent fall in his home. De Duve was cremated as he had willed, and his ashes were distributed among family members and friends.
From the 1950s onward, lobotomy began to be abandoned, first in the Soviet Union, where the procedure immediately garnered extensive criticism and was not widely employed, before being banned in December 1950, and then Europe. Derivatives of it such as stereotactic tractotomy and bilateral cingulotomy are still used.
The prostate's changes of shape, which facilitate the mechanical switch between urination and ejaculation, are mainly driven by the two longitudinal muscle systems running along the prostatic urethra. These are the urethral dilator (musculus dilatator urethrae) on the urethra's front side, which contracts during urination and thereby shortens and tilts the prostate in its vertical dimension thus widening the prostatic section of the urethral tube, and the muscle switching the urethra into the ejaculatory state (musculus ejaculatorius) on its backside. In case of an operation, e.g. because of benign prostatic hyperplasia (BPH), damaging or sparing of these two muscle systems varies considerably depending on the choice of operation type and details of the procedure of the chosen technique. The effects on postoperational urination and ejaculation vary correspondingly.
Sources: en.wikipedia.org
PT-141 is a laboratory code for bremelanotide, a synthetic peptide that activates melanocortin receptors. It has been developed both as an injectable pharmaceutical product and as a research chemical. The two contexts differ sharply in how identity, purity, and dosing are controlled.
It is neither a steroid nor a naturally occurring human hormone. Bremelanotide is a manufactured peptide that mimics part of the melanocortin signalling system by binding receptor proteins. Its effects come from receptor activation, not from replacing a circulating hormone.
The internal lactam bridge locks the peptide into a defined shape, which raises receptor affinity and slows enzymatic breakdown. Linear versions of the same sequence are less stable and bind more weakly. Ring geometry is therefore central to how the molecule behaves in the body.
It is a synthetic cyclic peptide that acts as an agonist at melanocortin receptors. It is not a hormone replacement therapy and not a vasodilator in the usual clinical sense, although it does affect vascular tone. Chemically it belongs to the melanocortin analogue family.